corneal clouding

Cataracts, Anterior Polar with Guttata

Clinical Characteristics
Ocular Features: 

The combination of corneal guttata and anterior polar cataracts has been reported in at least 4 multigenerational families.  Cataracts have their onset in the first decade of life, sometimes as early as 6 months but often are not noted until 3 to 4 years of age.  The polar opacities range in size from that of a small dot to 3 mm in diameter.  These progress slowly and become nearly stationary in early adulthood but can progress sufficiently to interfere with acuity and sometimes require removal by the 3rd or 4th decades of life.  The guttata also appear sometime after birth and are more pronounced centrally.  Histologically the stroma is normal but the epithelium shows some edematous changes and the Descemet membrane progressively thickens with age along with the corneal clouding.  Visual impairment early is generally caused by the lens opacity while later in life corneal edema is more likely the cause.

Vision across a variety of ages ranges from 20/20 to 20/40 in patients with more stationary disease.

Systemic Features: 

No associated systemic disease has been reported.

Genetics

This is a presumed autosomal dominant disorder resulting from heterozygous mutations in the TMCO3 gene (13q34).

Another type of autosomal dominant anterior polar cataract, CTAA2 (601202), but without corneal disease has been mapped to 17p13 and yet another (CTAA1) (115650) is associated with chromosomal aberrations.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Cataract extraction and corneal transplantation can improve vision but are seldom necessary.

References
Article Title: 

Corneal Dystrophy, Congenital Endothelial 1

Clinical Characteristics
Ocular Features: 

(OMIM has combined this disorder with PPCD1 (122000) based on genetic and clinical evidence.)

Early onset limbus-to-limbus corneal clouding is the outstanding feature.  Some asymmetry is often present.  Vision is minimally impaired if at all in many children but slow progression occurs and adults often become visually impaired.  Nystagmus does not develop.  Photophobia and tearing are common.  The corneal appearance can lead to the erroneous diagnosis of congenital glaucoma.  However, some infants actually do have congenital glaucoma as well leading some to suggest this may be a disorder of anterior chamber dysgenesis.  The edematous cornea may be of 2-3 times normal thickness.  It may appear generally hazy and sometimes has a diffuse ground glass appearance.  

The posterior surface often appears mottled and has been described as having a peau d'orange appearance.  The endothelium is attenuated or even absent histologically and abnormal, disorganized collagen fibrils have been found in a thickened Descemet layer by electron microscopy.  The remaining endothelial cells are often vacuolated and heaped in double layers, with some containing melanin granules.  Some atrophy and edema of the epithelium with partial loss of Bowman's can be seen histologically.

Systemic Features: 

No systemic abnormalities are found in this disorder.

Genetics

This is an autosomal dominant disorder that maps to a locus on chromosome 20 (20p11.2-q11.2).   The molecular defect seems to involve the promotor of OVOL2 (20p11.23).  It is of interest that the posterior polymorphous corneal dystrophy 1 (PPCD1, 122000) mutation has been mapped to the same pericentric region, and it has been suggested that the two conditions may be allelic. These are now combined into a single entity in OMIM. 

This disorder should not be confused with congenital endothelial dystrophy type 2, CHED2 (217700) which is autosomal recessive, has an earlier presentation, and maps to a different region of chromosome 20.  Harboyan syndrome (217400) has similar corneal features but maps to a different location on chromosome 20 and is associated with sensorineural deafness.

The nosology of the corneal dystrophies is still evolving.  In the 2015 edition of the IC3D, this condition designated CHED1 is eliminated based on clinical and pathologic similarities to those in posterior polymorphous corneal dystrophy 1 (PPCD1, 122000).  However, while the loci for PPCD2 and CHED1 are located in the same pericentric region of chromosome 20, the purported mutations occur in different genes. 

 

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Penetrating keratoplasty carries a good visual prognosis, even when done late in life.

References
Article Title: 

IC3D classification of corneal dystrophies--edition 2

Weiss JS, Moller HU, Aldave AJ, Seitz B, Bredrup C, Kivela T, Munier FL, Rapuano CJ, Nischal KK, Kim EK, Sutphin J, Busin M, Labbe A, Kenyon KR, Kinoshita S, Lisch W. IC3D classification of corneal dystrophies--edition 2. Cornea. 2015 Feb;34(2):117-59. Erratum in: Cornea. 2015 Oct;34(10):e32.

PubMed ID: 
25564336

Corneal Dystrophy, Schnyder

Clinical Characteristics
Ocular Features: 

Schnyder corneal dystrophy has its onset early in life as a haziness of the central cornea with some peripheral extension.  The stroma gradually becomes more hazy and eventually in about 50% of patients yellow-white crystalline deposits can be seen in an annular pattern in the Bowman layer and the adjacent stroma just beneath. The remaining layers of the cornea are not involved.  The needle-shaped crystals are often birefringent and composed of cholesterol and phospholipids. There is considerable variation in the progression of disease and in the symmetry of disease in the two eyes.  Visual acuity may be relatively good in young people but older patients with denser central opacification eventually require corneal transplantation for better vision.

Systemic Features: 

Some patients have hypercholesterolemia and hyperlipidemia.  Skin fibroblast cultures in one patient have shown cytoplasmic deposits consistent with unesterified cholesterol but another study failed to find such deposits in skin or conjunctiva.  Evidence points to a metabolic disorder of lipid metabolism in the cornea but the evidence for a more generalized systemic disorder is inconclusive.  Genu valgum has been reported in some patients.

Genetics

Schnyder crystalline dystrophy of the cornea results from a mutation in the UBIAD1 gene located on chromosome 1 (1p36.3).  Multiple mutations have been identified.  It is inherited in an autosomal dominant pattern.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Penetrating keratoplasty can be helpful in restoring vision but the corneal deposits and opacification often recur.  PTK procedures can also be beneficial.

References
Article Title: 

Schnyder corneal dystrophy

Weiss JS. Schnyder corneal dystrophy. Curr Opin Ophthalmol. 2009 Jul;20(4):292-8. Review.

PubMed ID: 
19398911

Genetic analysis of 14 families with Schnyder crystalline corneal dystrophy reveals clues to UBIAD1 protein function

Weiss JS, Kruth HS, Kuivaniemi H, Tromp G, Karkera J, Mahurkar S, Lisch W, Dupps WJ Jr, White PS, Winters RS, Kim C, Rapuano CJ, Sutphin J, Reidy J, Hu FR, Lu da W, Ebenezer N, Nickerson ML. Genetic analysis of 14 families with Schnyder crystalline corneal dystrophy reveals clues to UBIAD1 protein function. Am J Med Genet A. 2008 Feb 1;146(3):271-83. (Note: Erratum: Am. J. Med. Genet. 146A: 952-964, 2008.)

PubMed ID: 
18176953

Corneal Dystrophy, Macular

Clinical Characteristics
Ocular Features: 

Macular corneal dystrophy is a progressive, bilateral disorder with increasing corneal cloudiness throughout life. The onset of corneal haze is variable.  It can be seen in infancy but usually becomes apparent in the second or later decades of life.  Visual impairment can be severe, especially by mid-life.  The stroma, Descemet membrane, and endothelium are involved as keratocytes and endothelial cells accumulate intracytoplasmic vacuoles of glycosaminoglycans.  Corneal thickness is reduced, presumably due to abnormally dense packing of collagen fibrils in the stroma.  The epithelium does not seem to be involved.

Based on immunohistochemical profiles of inclusions, as well as phenotypic differences, attempts have been made to distinguish at least three types of macular dystrophy, I, IA, and II.  This may not be justified as the same gene is involved, and especially since several types have been described within the same inbred family.  Most likely these are variations in the phenotypic expression of the same gene, a  feature of many genetic disorders.

Systemic Features: 

No extraocular abnormalities have been associated with this disorder.  However, variations in serum levels of antigenic keratin sulfate have been found.

Genetics

Homozygous mutations in the CHST6 gene (16q22) are responsible for this autosomal recessive corneal dystrophy.  More than 100 mutations have been found.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Full thickness and deep anterior lamellar keratoplasty can improve vision and relieve symptoms but the disease can recur in the graft.  More than 40% of grafts have recurrent opacities after 10 years.  The recurrence risk is higher in patients with disease onset at age 18 years or younger and in those who had keratoplasty before the age of 30 years.

References
Article Title: 

Macular Corneal Dystrophy: A Review

Aggarwal S, Peck T, Golen J, Karcioglu ZA. Macular Corneal Dystrophy: A Review. Surv Ophthalmol. 2018 Mar 28. pii: S0039-6257(17)30101-7. doi: 10.1016/j.survophthal.2018.03.004. [Epub ahead of print] Review.

PubMed ID: 
29604391

Peters-Plus Syndrome

Clinical Characteristics
Ocular Features: 

Peters anomaly (306229) usually occurs as an isolated ocular malformation and is often unilateral.  However, in some patients with bilateral involvement it is part of a systemic syndrome or other congenital conditions such as chromosomal deletions and the fetal alcohol syndrome.  It is called Peters Plus syndrome in the condition described here because of the association of a specific combination of systemic features.

The ocular features are consistent with dysgenesis of the anterior chamber.  The clinical picture is highly variable but generally consists of iris adhesions to the cornea centrally (classical Peters anomaly), occasionally lenticular adhesions as well, and thinning of the central corneal stroma.  As a result, the cornea may become edematous, cataracts may develop, and glaucoma is common.

Systemic Features: 

Peters-plus syndrome consists of Peters anomaly plus various degrees of developmental delays and intellectual deficits, short digits and short stature, and cleft lip and palate.  The facies is said to be characteristic due to a prominent forehead, narrow palpebral fissures, and a cupid's bow-shaped upperlip. There may be preauricular pits present and the neck is often broad.  The ears may be prominent.  Congenital heart defects are present in a third of patients and a few have genitourinary anomalies.

Genetics

This is an autosomal recessive disorder of glycosylation caused by a mutation in the B3GALTL gene on chromosome 13 (13q12.3).  At least some patients have a splicing mutation in this gene leading to a skipping of exon 8.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Treatment is directed at sight preservation by correcting the major ocular defects such as glaucoma and iridocorneal adhesions.  Corneal transplants and cataract removal are sometimes required.  Releasing the anterior synechiae can lead to significant clearing of the corneal edema.  Growth hormone replacement therapy may be beneficial.

References
Article Title: 

The Peters' plus syndrome: a review

Maillette de Buy Wenniger-Prick LJ, Hennekam RC. The Peters' plus syndrome: a review. Ann Genet. 2002 Apr-Jun;45(2):97-103. Review.

PubMed ID: 
12119218

Corneal Dystrophy, Congenital Endothelial 2

Clinical Characteristics
Ocular Features: 

Corneal clouding is usually evident at birth and in virtually all cases in the first decade of life.   Corneal edema is usually progressive and often leads to stromal scarring, neovascularization, and deposition of plaques eventually.  The ground glass appearance of the cornea at least initially is most pronounced peripherally.  When the ground glass appearance is present in young children, it may lead to the misdiagnosis of congenital glaucoma and some children have had glaucoma surgery.  However, no anatomic abnormalities of the anterior chamber angle have been observed and glaucoma does not seem to occur in this disorder as it does in CHED1.  Photophobia and tearing are uncommon. 

The corneal epithelium may become atrophic with partial loss of Bowman's membrane replaced by subepithelial fibrosis.  Corneal sensitivity is normal.  The stroma may have spheroidal degeneration resembling posterior polymorphous dystrophy.  Generalized edema may lead to marked thickening of the entire cornea.  The endothelium undergoes degeneration and cell loss is common, while those that remain often contain melanin granules.  Descemet's membrane is greatly thickened.  This condition may be stable in some individuals while others clearly have evidence of progression, and a few have some regression in childhood.  Vision may be quite good and few patients develop nystagmus.

Systemic Features: 

No systemic abnormalities have been reported.

Genetics

This is an autosomal recessive disorder resulting from mutations in the SLC4A11 gene located on chromosome 20 (20p13-12).  This disorder must be distinguished from Harboyan syndrome (#217400, CDPD1) from which it differs by the absence of neurosensory deafness.  The two disorders are allelic, however.  A clinically similar but less severe and genetically distinct form of congenital endothelial dystrophy, CHED1 (121700), can have a later age of presentation, maps to a different region of chromosome 20 ( 20p11.2-q11.2), and is inherited in an autosomal dominant pattern. 

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Corneal transplantation can be successful in restoring vision in 90% of cases, even when performed in adults.

References
Article Title: 

Congenital hereditary

McCartney A, Rice NS, Garner A, Steele AD. Congenital hereditary
corneal oedema of Maumenee: its clinical features, management, and pathology.
Br J Ophthalmol. 1987 Feb;71(2):130-44.

PubMed ID: 
3548808

Tangier Disease

Clinical Characteristics
Ocular Features: 

This disorder of lipoprotein metabolism is associated in many cases with corneal infiltrates, cicatricial ectropion, poor lid closure, and exposure keratopathy.  The corneal clouding alone generally cause little reduction of acuity but those with poor lid function and exposure keratopathy may have severe vision loss.  There may be weakness in the periorbital and lid muscles.  The corneal infiltration occurs late in life but is progressive with older individuals having the greatest visual impairment.  The corneal infiltrates are described as a “dot-like haze”, more prominent centrally and located in the stroma.  On electron microscopy, deposits in the conjunctiva are described as birefringent lipid particles located in pericytes and fibrocytes.  Lipid deposition occurs throughout the body including the conjunctiva.  Corneal hypesthesia has been reported.

In a series of 13 patients, ectropion and corneal scarring were reported in 3 and corneal infiltrates in 9.  Four had orbicular muscle weakness.  The latter together with corneal hypesthesia may be the earliest ocular signs of Tangier disease and should suggest the diagnosis even before the corneal clouding occurs.

Systemic Features: 

Patients with Tangier disease have significant enlargement of the liver, spleen and lymph nodes.  The tonsils are also frequently enlarged and have a characteristic yellow-orange  coloration.  The enlargement of these organs is due to lipid infiltration.  Plasma levels of cholesterol and HDL are characteristically slightly low while triglycerides are mildly elevated.  Peripheral neuropathy and muscle atrophy can be debilitating.  Severe coronary artery disease is common with onset sometime in the 5th decade.

Genetics

Tangier disease is an autosomal recessive disorder resulting from mutations in the ATP-binding cassette-1 gene ABCA1 (9p31.1) located in exon 22.  Parental consanguinity is common.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

No treatment is available for this disorder beyond local organ treatment as indicated.
 

References
Article Title: 

Ocular complications of Tangier disease

Pressly, T. A.; Scott, W. J.; Ide, C. H.; Winkler, A.; Reams, G. P. : Ocular complications of Tangier disease. Am. J. Med. 83: 991-994, 1987.

PubMed ID: 
3314502

LCAT Deficiency

Clinical Characteristics
Ocular Features: 

Norum disease and fish-eye disease are discussed as a single entry in this database because they are both caused by mutations in the same gene (LCAT).  Most patients are diagnosed as young adults.  Corneal opacities are may be the only clinically significant abnormality in fish-eye disease whereas anemia and renal complications are more significant in Norum disease.   Lipid deposition in the cornea is responsible for the corneal opacities and may cause significant reduction in vision.  However, opacities are concentrated near the limbus.  The cornea in fish-eye disease has twice the normal amount of cholesterol and vacuoles in the stroma and Bowman's.  Vision ranges from 20/40 to hand motions, with onset in the first two decades and progression throughout life.  The opacities form a mosaic pattern of small dot-like grey-white-yellow opacities.  The fish-eye designation comes from the corneal clouding resembling boiled fish eyes.

Systemic Features: 

Lecithin:cholesterol acyltransferase (LCAT) is a disorder of lipoprotein metabolism resulting in reduced plasma cholesterol esterifying activity.  The mutation leading to Norum disease causes normocytic hemolytic anemia with significant proteinuria secondary to renal failure.  However, patients with fish-eye disease do not have anemia or renal disease.  Red blood cells may have increased cholesterol content and foam cells are found in bone marrow and in the glomerular tufts of the kidney.  Peripheral neuropathy is sometimes present.   Circulating cholesterol, triglycerides and phospholipids are elevated whereas high-density lipoprotein (HDL), apoA-I and apoA-II are reduced.  However, premature atherosclerosis is not a feature contrary to expectations.  

LCAT deficiency does not have hepatomegaly, splenomegaly or enlarged lymph glands as found in another disorder of lipoprotein metabolism with low HDL levels known as Tangier disease (205400).

Genetics

Complete LCAT deficiency (Norum) disease and partial deficiency (fish-eye disease) are autosomal recessive disorders secondary to mutations in the LCAT gene located on chromosome 16 (16q22.1).  The mutation is located in codon 123 in fish-eye disease and in codon 4 of Norum disease.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Severe visual impairment secondary to corneal clouding is an indication for corneal transplantation.  Renal failure may require renal transplantation.
 

References
Article Title: 

Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease.

Rader, D. J.; Ikewaki, K.; Duverger, N.; Schmidt, H.; Pritchard, H.; Frohlich, J.; Clerc, M.; Dumon, M.-F.; Fairwell, T.; Zech, L.; Santamarina-Fojo, S.; Brewer, H. B., Jr. : Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest. 93: 321-330, 1994.

PubMed ID: 
8282802

A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.

Funke, H.; von Eckardstein, A.; Pritchard, P. H.; Albers, J. J.; Kastelein, J. J. P.; Droste, C.; Assmann, G. : A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.  Proc. Nat. Acad. Sci. 88: 4855-4859, 1991.

PubMed ID: 
2052566

Pages

Subscribe to RSS - corneal clouding